<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01417494</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000706869</org_study_id>
    <secondary_id>FFCD-PRODIGE-20</secondary_id>
    <secondary_id>EU-21120</secondary_id>
    <secondary_id>2010-022080-34</secondary_id>
    <nct_id>NCT01417494</nct_id>
  </id_info>
  <brief_title>1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>Evaluation of Bevacizumab Combined With First Line Chemotherapy in Patients Aged 75 and Over Suffering From Metastatic Colorectal Adenocarcinoma. Phase II Randomized - Intergroup Trial: FFCD, FNCLCC, GERICO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, irinotecan&#xD;
      hydrochloride, and oxaliplatin, work in different ways to stop the growth of tumor cells,&#xD;
      either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as&#xD;
      bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells&#xD;
      to grow and spread. Others find tumor cells and help kill them or carry tumor-killing&#xD;
      substances to them. Giving bevacizumab together with combination chemotherapy may be a better&#xD;
      way to block tumor growth. It is not yet known whether combination chemotherapy is more&#xD;
      effective when given together with or without bevacizumab in treating patients with&#xD;
      colorectal cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying the side effects of giving bevacizumab&#xD;
      together with first-line chemotherapy and to see how well it works in treating older patients&#xD;
      with metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate composite efficacy and safety, in terms of objective response or tumoral&#xD;
           stability by RECIST criteria and no deterioration in the Spitzer QoL Index score of ≥ 2&#xD;
           points at 4 months, in older patients with unresectable metastatic colorectal&#xD;
           adenocarcinoma treated with bevacizumab and first-line chemotherapy.&#xD;
&#xD;
        -  To evaluate tolerance, in terms of no grade 4 arterial hypertension, grade 3-4&#xD;
           thromboembolic event, grade 3-4 cardiac insufficiency, and hospitalization not linked to&#xD;
           chemotherapy, in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate toxicity in these patients.&#xD;
&#xD;
        -  To assess time to deterioration of autonomy in these patients.&#xD;
&#xD;
        -  To assess survival with no deterioration of autonomy of these patients.&#xD;
&#xD;
        -  To evaluate time to deterioration of quality of life of these patients.&#xD;
&#xD;
        -  To evaluate percentage of patients who received at least 2/3 of the protocol treatment&#xD;
           at month 4.&#xD;
&#xD;
        -  To assess time to treatment failure in these patients.&#xD;
&#xD;
        -  To assess progression-free survival and global survival of these patients.&#xD;
&#xD;
      Tertiary&#xD;
&#xD;
        -  To test for predictive factors of treatment success identified during the geriatric&#xD;
           evaluation, according to the main judgment criterion, and analysis of the evolution of&#xD;
           geriatric parameters during follow-up int these patients. (Exploratory)&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to chemotherapy&#xD;
      (monotherapy vs double chemotherapy), primary tumor (resected vs non-resected), and&#xD;
      quality-of-life score evaluated by the Spitzer QoL Index (0-3 vs 4-7 vs 8-10). Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm A: Patients receive 1 of the following regimens according to the discretion of the&#xD;
           investigator:&#xD;
&#xD;
             -  Simplified LV5FU2 comprising leucovorin calcium IV over 2 hours on days 1 and 15&#xD;
                and fluorouracil IV over 46 hours beginning on days 1 and 15.&#xD;
&#xD;
             -  FOLFIRI comprising leucovorin calcium IV over 2 hours on days 1 and 15; irinotecan&#xD;
                hydrochloride IV over 2 hours on days 1 and 15; and fluorouracil IV over 46 hours&#xD;
                beginning on days 1 and 15.&#xD;
&#xD;
             -  FOLFOX4 comprising oxaliplatin IV over 2 hours on days 1 and 15; leucovorin calcium&#xD;
                IV over 2 hours on days 1 and 15; and fluorouracil IV over 46 hours beginning on&#xD;
                days 1 and 15.&#xD;
&#xD;
      All treatment regimens repeat every 4 weeks for at least 6 months in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm B: Patients receive chemotherapy as in arm A. Patients also receive bevacizumab IV&#xD;
           over 90 minutes on days 1 and 15. Treatment repeats every 4 weeks for at least 6 months&#xD;
           in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed periodically. Blood specimens are collected for evaluation of the&#xD;
      quantification of circulating cells for early prediction of response to treatment.&#xD;
&#xD;
      After completion of study therapy, patients are followed up every 2-3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy, in terms of objective response or tumoral stability by RECIST criteria</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Deterioration in the Spitzer QoL Index score of ≥ 2 points at baseline and at 4 months</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerance, in terms of no grade 4 arterial hypertension, grade 3-4 thromboembolic event, grade 3-4 cardiac insufficiency, and hospitalization not related to chemotherapy</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deterioration of autonomy</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival with no deterioration of autonomy</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy associated with bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy (FOLFIRI, FOLFOX, LV5FU2) associated with bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy (FOLFIRI, FOLFOX, LV5FU2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen)</intervention_name>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab</intervention_name>
    <arm_group_label>Chemotherapy associated with bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic colorectal adenocarcinoma&#xD;
&#xD;
               -  Unresectable disease&#xD;
&#xD;
          -  Measurable disease by RECIST criteria&#xD;
&#xD;
          -  No cerebral metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Polynuclear neutrophils &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Proteinuria ≤ 1 g on 24-hour urine collection&#xD;
&#xD;
          -  No unresolved intestinal occlusion or subocclusion&#xD;
&#xD;
          -  No other progressive or unstabilized malignant tumor within the past 2 years&#xD;
&#xD;
          -  No progressive gastroduodenal ulcer, wound, or bone fracture&#xD;
&#xD;
          -  No active cardiac disease including any of the following:&#xD;
&#xD;
               -  Hypertension not adequately controlled&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Poorly controlled angina&#xD;
&#xD;
               -  Decompensated congestive cardiac insufficiency&#xD;
&#xD;
          -  No history of arterial thromboembolism or any of the following within the past 12&#xD;
             months:&#xD;
&#xD;
               -  Cerebrovascular accident&#xD;
&#xD;
               -  Transient ischemic attack&#xD;
&#xD;
               -  Subarachnoid hemorrhage&#xD;
&#xD;
          -  No history of distal or visceral ischemic arterial pathology ≥ grade 2 within the past&#xD;
             12 months&#xD;
&#xD;
          -  No history of life-threatening pulmonary embolism within the past 6 months&#xD;
&#xD;
          -  Must have completed the geriatric self-administered questionnaire and the geriatric&#xD;
             &quot;team&quot; questionnaire (including the Spitzer QoL Index)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease&#xD;
&#xD;
               -  More than 6 months since adjuvant chemotherapy after resection of the primary&#xD;
                  tumor&#xD;
&#xD;
          -  More than 4 weeks since major surgery, excluding biopsy&#xD;
&#xD;
          -  More than 4 weeks since radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Aparicio</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Avicenne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Aparicio T, Bouché O, Taieb J, Maillard E, Kirscher S, Etienne PL, Faroux R, Khemissa Akouz F, El Hajbi F, Locher C, Rinaldi Y, Lecomte T, Lavau-Denes S, Baconnier M, Oden-Gangloff A, Genet D, Paillaud E, Retornaz F, François E, Bedenne L; for PRODIGE 20 Investigators. Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. Ann Oncol. 2018 Nov 1;29(11):2270. doi: 10.1093/annonc/mdx808.</citation>
    <PMID>29718089</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 13, 2011</study_first_submitted>
  <study_first_submitted_qc>August 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2011</study_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>stage IVA colon cancer</keyword>
  <keyword>stage IVB colon cancer</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>stage IVA rectal cancer</keyword>
  <keyword>stage IVB rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

